Drugs / TP-1454
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04328740 | Jul 2020 → Apr 2025 | anal carcinoma | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TP-1454 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04328740 ↗ |
| Route | Oral | “orally administered TP-1454” NCT04328740 ↗ |